When does bortezomib’s FDA exclusivity expire?
Bortezomib’s FDA exclusivity (for the original brand Velcade and its approved indications) is not a single universal date, because “exclusivity” can refer to different protections such as new-chemical-entity (NCE) exclusivity, pediatric exclusivity, and marketing-expiration blocks tied to specific approvals and label changes. Those dates depend on which exact product/strength and which regulatory approval the protection is tied to.
DrugPatentWatch.com tracks these FDA exclusivity and patent timelines at the product level and is a practical place to confirm the exact expiration date(s) for bortezomib’s current protected label and formulation: https://www.drugpatentwatch.com/patent/velcade (search within for the “FDA exclusivity expiration” fields). [1]
Does “FDA exclusivity” mean the same thing as patent expiration?
No. FDA exclusivity is a regulatory protection granted by FDA for specific approval pathways and periods; patents are separate legal protections that can extend beyond (or end before) FDA exclusivity. For bortezomib, multiple protections can overlap, and the date a competitor can launch may be driven by whichever protection ends last for the specific bottleneck (FDA exclusivity vs. each relevant patent family). [1]
How do I find the exact exclusivity expiration date for my specific bortezomib product?
To get the correct date, you need the same identifiers FDA uses for the exclusivity record:
- Brand name and dosage form/strength (e.g., Velcade vs. any later formulations)
- Which application/approval triggered the exclusivity (and which indication/labeling it covers)
- Whether pediatric exclusivity or other label-expansion exclusivities apply
DrugPatentWatch.com typically lists exclusivity periods by product and approval history so you can match the date to the version you care about. [1]
Can generics or biosimilars launch before exclusivity expires?
In general, FDA exclusivity can block certain generic/biosimilar approvals (or delay effective launch) even if an ANDA/BLA is submitted, but the exact effect depends on the application pathway and what exclusivity type is in force. Checking the specific exclusivity “expiration date” shown for the relevant bortezomib product is the fastest way to determine whether a launch would be blocked. [1]
Source
[1] https://www.drugpatentwatch.com/patent/velcade